Picard Medical, Inc. (PMI) earnings per share
| Period | End | Diluted | Filed |
|---|---|---|---|
| FY 2025 | 2025-12-31 | — | 2026-03-30 |
| FY 2025 | 2024-12-31 | — | 2026-03-30 |
| Period | End | Diluted | Filed |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | — | 2026-05-15 |
| Q4 2025 | 2025-12-31 | — | 2026-03-30 |
| Q3 2025 | 2025-09-30 | — | 2025-11-14 |
| Q2 2025 | 2025-03-31 | — | 2025-09-12 |
| Q4 2025 | 2024-12-31 | — | 2026-03-30 |
| Q3 2025 | 2024-09-30 | — | 2025-11-14 |
| Period | End | FCF / Share | Filed |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | -$0.05 | 2026-05-15 |
| Q2 2025 | 2025-03-31 | -$0.33 | 2025-09-12 |
Methodology
Annual rows come from the filer's 10-K and Q1–Q3 rows from
the matching 10-Q; Q4 is derived as full-year minus nine-month
YTD because XBRL doesn't tag Q4 as its own period.
EPS Basic and EPS Diluted
are reported directly by the filer.
FCF / Share is computed as
(Operating Cash Flow − Capital Expenditures) ÷ Diluted
Shares Outstanding. When SEC companyfacts omits the
direct diluted-share concept for an older period, we
imply it from NetIncomeLoss ÷ EarningsPerShareDiluted.
For financial filers whose operating cash flow includes
customer-fund activity (e.g. Mercado Pago deposits),
FCF may materially exceed net income because the fintech
float is recorded inside OCF under US GAAP.
For the exact XBRL concepts and formulas, see the methodology reference for EPS, FCF per share, the Q4 derivation, and split adjustment.
PMI CIK 0002030617 Source: EDGAR filings · all facts